Alnylam Pharmaceuticals (ALNY.O) said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration declined to approve the medication despite a favorable recommendation from its advisers.
said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration declined to approve the medication despite a favorable recommendation from its advisers.
The rejection was a rare instance of the regulator going against its advisory panel's backing for a drug. The FDA's outside panel of experts had last month"We are surprised" by the FDA's decision, RBC capital analyst Luca Issi said in a note. Alnylam said it will focus on another drug candidate, vutrisiran, an under-the-skin injection in late-stage trials to treat ATTR amyloidosis-related cardiomyopathy.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letterCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Read more »
Alnylam Stock Is Dropping on Surprising FDA RejectionDrugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside...
Read more »
Exxon, Lockheed, Northrop, Delta, Mirati, Alnylam, SolarEdge, and More Stock Market MoversExxon and Chevron rise after a jump in oil prices following the weekend attack on Israel from Hamas, Lockheed Martin, Northrop Grumman and other defense...
Read more »
FDA Adds Warning To Ozempic Label About Ileus, Intestinal BlockageI am a writer, journalist, professor, systems modeler, computational, AI, and digital health expert, medical doctor, avocado-eater, and entrepreneur, not always in that order. Currently, I am a Professor of Health Policy and Management at the City University of New York (CUNY) School of Public Health, Executive Director of PHICOR (PHICORteam) and Center for Advanced Technology and Communication in Health (CATCH), and founder and CEO of Symsilico. My previous positions include serving as Profess
Read more »
Novavax ships millions of updated COVID-19 vaccine doses after FDA clearanceVaccine manufacturer Novavax Inc. has announced the shipment of millions of doses of its updated COVID-19 vaccines to distributors following approval from U.S. regulators.
Read more »
FDA-approved injection can restore collagen and improve aging signsThe Food and Drug Administration has approved an easy and effective method of restoring collagen in the skin without having to ingest endless supplements.
Read more »